Literature DB >> 27145377

CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes.

Meghan G Lubner1, Nicholas Stabo1, E Jason Abel2, Alejandro Munoz Del Rio1, Perry J Pickhardt1.   

Abstract

OBJECTIVE: The purpose of the present study is to determine whether CT texture features of newly diagnosed primary renal cell carcinomas (RCCs) correlate with pathologic features and oncologic outcomes.
MATERIALS AND METHODS: CT texture analysis was performed on large (> 7 cm; mean size, 9.9 cm) untreated RCCs in 157 patients (52 women and 105 men; mean age, 60.3 years). Measures of tumor heterogeneity, including entropy, kurtosis, skewness, mean, mean of positive pixels, and SD of pixel distribution histogram were derived from multiphasic CT using various filter settings: unfiltered (spatial scaling factor, 0), fine (spatial scaling factor, 2), medium (spatial scaling factor, 3-4), or coarse (spatial scaling factor, 5-6). Texture values were correlated with histologic subtype, nuclear grade, pathologic stage, and clinical outcome.
RESULTS: When a coarse filter setting (spatial scaling factor, 6) was used, entropy on portal venous phase CT images was positively associated with clear cell histologic findings (odds ratio [OR], 134; 95% CI, 16-1110; p < 0.001) and was negatively associated with non-clear cell subtype findings (papillary spatial scale factor, 6; OR, 0.016; 95% CI, 0.002-0.132; p < 0.001). ROC curve analysis for entropy (on portal venous phase images obtained with a spatial scaling factor of 6) revealed an AUC of 0.943 (95% CI, 0.892-0.993) for clear cell histologic findings, with similar values noted for non-clear cell histologic findings. The mean of positive pixels and the SD of the pixel distribution histogram were statistically significantly associated with histologic cell type in a similar fashion. Entropy, the SD of the pixel distribution histogram, and the mean of positive pixels were associated with nuclear grade, most prominently when fine or medium texture filters were used (p < 0.05). There was a statistically significant association of texture features noted on unenhanced CT, including the SD of the pixel distribution histogram, the mean of positive pixels, and entropy, with the time to disease recurrence and death due to disease (e.g., for entropy noted on unenhanced CT images obtained with a spatial scaling factor of 6, the hazard ratio was 3.49 [95% CI, 1.55-7.84]; p = 0.002).
CONCLUSION: CT texture features (in particular, entropy, the mean of positive pixels, and the SD of the pixel distribution histogram) are associated with tumor histologic findings, nuclear grade, and outcome measures. The contrast phase does seem to affect heterogeneity measures.

Entities:  

Keywords:  CT texture; heterogeneity; renal cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27145377     DOI: 10.2214/AJR.15.15451

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  36 in total

1.  Assessment of multiphasic contrast-enhanced MR textures in differentiating small renal mass subtypes.

Authors:  Uyen N Hoang; S Mojdeh Mirmomen; Osorio Meirelles; Jianhua Yao; Maria Merino; Adam Metwalli; W Marston Linehan; Ashkan A Malayeri
Journal:  Abdom Radiol (NY)       Date:  2018-12

2.  Radiomics analysis of 18F-Choline PET/CT in the prediction of disease outcome in high-risk prostate cancer: an explorative study on machine learning feature classification in 94 patients.

Authors:  Pierpaolo Alongi; Alessandro Stefano; Albert Comelli; Riccardo Laudicella; Salvatore Scalisi; Giuseppe Arnone; Stefano Barone; Massimiliano Spada; Pierpaolo Purpura; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giorgio Russo
Journal:  Eur Radiol       Date:  2021-01-14       Impact factor: 5.315

3.  CT texture analysis in the differentiation of major renal cell carcinoma subtypes and correlation with Fuhrman grade.

Authors:  Yu Deng; Erik Soule; Aster Samuel; Sakhi Shah; Enming Cui; Michael Asare-Sawiri; Chandru Sundaram; Chandana Lall; Kumaresan Sandrasegaran
Journal:  Eur Radiol       Date:  2019-05-24       Impact factor: 5.315

4.  MR Imaging of Rectal Cancer: Radiomics Analysis to Assess Treatment Response after Neoadjuvant Therapy.

Authors:  Natally Horvat; Harini Veeraraghavan; Monika Khan; Ivana Blazic; Junting Zheng; Marinela Capanu; Evis Sala; Julio Garcia-Aguilar; Marc J Gollub; Iva Petkovska
Journal:  Radiology       Date:  2018-03-07       Impact factor: 11.105

Review 5.  Deep learning with convolutional neural network in radiology.

Authors:  Koichiro Yasaka; Hiroyuki Akai; Akira Kunimatsu; Shigeru Kiryu; Osamu Abe
Journal:  Jpn J Radiol       Date:  2018-03-01       Impact factor: 2.374

6.  [A radiomic approach to differential diagnosis of renal cell carcinoma in patients with hydronephrosis and renal calculi].

Authors:  Hang Zhang; Qing Li; Shulong Li; Jianhua Ma; Jing Huang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-05-30

Review 7.  Radiomics in Kidney Cancer: MR Imaging.

Authors:  Alberto Diaz de Leon; Payal Kapur; Ivan Pedrosa
Journal:  Magn Reson Imaging Clin N Am       Date:  2019-02       Impact factor: 2.266

8.  Decoding incidental ovarian lesions: use of texture analysis and machine learning for characterization and detection of malignancy.

Authors:  Hyesun Park; Lei Qin; Pamela Guerra; Camden P Bay; Atul B Shinagare
Journal:  Abdom Radiol (NY)       Date:  2020-07-29

Review 9.  Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review.

Authors:  Natally Horvat; David D B Bates; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2019-11

10.  Effect of phase of enhancement on texture analysis in renal masses evaluated with non-contrast-enhanced, corticomedullary, and nephrographic phase-enhanced CT images.

Authors:  Kathleen Nguyen; Nicola Schieda; Nick James; Matthew D F McInnes; Mark Wu; Rebecca E Thornhill
Journal:  Eur Radiol       Date:  2020-09-10       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.